Myungin Pharm
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Myungin Pharm makes prescription medicines that act on the central nervous system, drugs used to treat conditions such as stroke, Parkinson's disease, schizophrenia, and depression, as well as over-the-counter products including a gum-health supplement and a constipation remedy.
Its medicines are prescribed by doctors in South Korea and the company also supplies global pharmaceutical partners in markets including the United States, Europe, China, and Japan. Listed on KOSPI, South Korea's main stock exchange, the company derives nearly all of its revenue from pharmaceutical sales, with prescription drugs making up the large majority of that.
Summary is AI-generated and may contain errors · figures from DART filings
The company covers the full production chain, from active-ingredient synthesis through to finished-dose manufacturing, built to the standards required by current Good Manufacturing Practice (cGMP) guidelines.
Myungin Pharm in five facts
What does Myungin Pharm do?
Myungin Pharm makes prescription medicines that act on the central nervous system, drugs used to treat conditions such as stroke, Parkinson's disease, schizophrenia, and depression, as well as over-the-counter products including a gum-health supplement and a constipation remedy.
Where is Myungin Pharm listed and in which sector?
Myungin Pharm (Korean name: 명인제약) trades under KRX code 317450 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Myungin Pharm?
Its market capitalisation was US$452.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Myungin Pharm's latest annual revenue and operating profit?
For fiscal year 2025, Myungin Pharm reported revenue of US$216.8M, operating profit of US$69.8M and net income of US$61.5M, per its annual report on DART (data retrieved from DART on 2026-10-02).
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Cash/in-kind dividend decision
Myungin Pharm updated its declared cash dividend of US$0.35 per share, equal to about 1.2% of the recent share price.
Dividend · Aug 6 · 2 versions - Operating results (preliminary) (fair disclosure)
Myungin Pharm filed provisional (unaudited) separate results for Q2 2026: revenue of US$53.6M (+5.4% year on year), operating profit of US$19M (+9.8% year on year) and net income of US$16.7M (+16% year on year).
Earnings · Jul 31 - Cash/in-kind dividend decision
Myungin Pharm declared a cash dividend of US$1.03 per share.
Dividend · Feb 3